<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737670</url>
  </required_header>
  <id_info>
    <org_study_id>SULO-TINNITUS</org_study_id>
    <nct_id>NCT02737670</nct_id>
  </id_info>
  <brief_title>Sulodexide Efficacy in Chronic Idiopathic Subjective Tinnitus</brief_title>
  <acronym>SECIST</acronym>
  <official_title>Randomized Double Blind Controlled Trial on Sulodexide Efficacy in Chronic Idiopathic Subjective Tinnitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Joseph University, Beirut, Lebanon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St Joseph University, Beirut, Lebanon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this prospective randomized and double blind controlled study is to evaluate
      the efficacy and safety of Sulodexide (25 mg) in the treatment of chronic idiopathic
      subjective tinnitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic idiopathic subjective tinnitus, since at least 1 year, re recruited
      from our Ear, Nose and Throat (ENT) clinic. After verification of inclusion and exclusion
      criteria, patients consenting to enter the study are assigned randomly to one of the
      following groups: 1- Sulodexide 25 mg for 40 days 2- Placebo for 40 days. Clinical evaluation
      of the patient is performed; tinnitus is assessed according to Tinnitus Handicap Inventory
      score, Mini Tinnitus Questionnaire score. Adverse effects are also noted. Patients are
      followed at 40 days post-treatment and outcome measures are assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tinnitus Handicap Inventory (THI)</measure>
    <time_frame>At day 0 and at 40 days</time_frame>
    <description>Assessment of changes in THI questionnaire score between Day 40 and 0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mini Tinnitus Questionnaire (Mini-TQ)</measure>
    <time_frame>At day 0 and at 40 days</time_frame>
    <description>Assessment of changes in Mini-TQ questionnaire score between Day 40 and 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>reporting adverse effects by the patient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Tinnitus, Subjective</condition>
  <arm_group>
    <arm_group_label>Sulodexide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sulodexide 25 mg twice per day for 40 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 tablet twice per day for 40 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulodexide</intervention_name>
    <description>25 mg morning and evening for 40 days</description>
    <arm_group_label>Sulodexide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet morning and evening for 40 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Tinnitus for minimum of 1 year

          -  Absence of psychiatric or neurological diseases

          -  Absence of any disease that explains tinnitus

          -  Noise-induced hearing loss

          -  Cochlear and retro-cochlear damage

        Exclusion Criteria:

          -  Conductive hearing loss

          -  Mixed hearing loss

          -  Meniere's disease

          -  Systemic vascular disease

          -  Diabetic disease

          -  Vestibular schwannoma

          -  Cerebello-pontine angle tumors

          -  Pulsatile tinnitus

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elias Eter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine - St Joseph University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Jospeh University</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2016</study_first_submitted>
  <study_first_submitted_qc>April 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St Joseph University, Beirut, Lebanon</investigator_affiliation>
    <investigator_full_name>Dr Joseph Maarrawi</investigator_full_name>
    <investigator_title>Head of the Laboratory of Neurosciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

